Ironwood Pharmaceuticals
IRWD
4.70
-0.01
-0.21%
Ironwood Pharmaceuticals
US · IRWD
#3609 by market cap
4.70
-0.01
-0.21%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 14 in the most recent period (2026/Q3).
- Total institutional ownership fell 4.4 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 95.82% -4.36pp
- Institutions
- 275 +14
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund57.24%
Hedge Fund29.24%
Public Company6.78%
Individual/Insider3.23%
Private Company0.90%
Government Pension Fund0.80%
Bank/Investment Bank0.29%
Family Office/Trust0.25%
Insurance Company0.19%
Other1.07%
Top holders as of 2026-09-30
BlackRock
11.16% · 18.48M sh
Armistice Capital LLC
8.42% · 13.93M sh
Sarissa Capital Management LP
5.55% · 9.19M sh
Renaissance Technologies Corp.
4.86% · 8.04M sh
State Street Global Advisors
4.06% · 6.72M sh
Vanguard Capital Management, LLC
4.01% · 6.63M sh
AQR Capital Management
3.80% · 6.29M sh
Bank of America Corporation
3.15% · 5.22M sh
Vanguard Portfolio Management, LLC
3.06% · 5.06M sh
Acadian Asset Management LLC
3.05% · 5.05M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 28 buys · 22 sells
| Name | Role | Stake |
|---|---|---|
| Thomas McCourt | Chief Executive Officer | 1.04% |
| Mark Currie | Independent Director | 0.41% |
| Michael Shetzline | Former Chief Medical Officer, Senior VP and Head of Research & Drug Development | 0.23% |
| Alexander Denner | Independent Director | 0.20% |
| Jon Duane | Independent Director | 0.15% |
| Julie McHugh | Independent Chairperson | 0.15% |
| Tammi Gaskins | Senior Vice President & Chief Commercial Officer | 0.14% |
| Jay Shepard | Independent Director | 0.14% |
| Marla Kessler | Independent Director | 0.14% |
| John Minardo | Chief Legal Officer | 0.14% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-15 | Tammi Gaskins | Senior Vice President & Chief Commercial Officer | Intent to Sell (Form 144) | -6,666 | $4.85 |
| 2026-09-23 | Michael Shetzline | Former Chief Medical Officer, Senior VP and Head of Research & Drug Development | Intent to Sell (Form 144) | -83,306 | $4.53 |
| 2026-09-14 | Alexander Denner | Independent Director | Other Acquisition | +3,694 | -- |
| 2026-07-19 | Jeffrey Silber | Chief Medical Officer, Head of Research & Drug Development | Other Acquisition | +137,036 | -- |
| 2026-07-06 | Ronald Silver | Senior VP, Interim CFO, Corporate Controller & Chief Accounting Officer | Automatic Disposition | -127,890 | $4.52 |
| 2026-06-15 | Jay Shepard | Independent Director | Other Acquisition | +63,481 | -- |
| 2026-06-15 | Alexander Denner | Independent Director | Other Acquisition | +67,546 | -- |
| 2026-06-15 | Mark Currie | Independent Director | Other Acquisition | +63,481 | -- |
| 2026-06-15 | Catherine Moukheibir | Independent Director | Other Acquisition | +63,481 | -- |
| 2026-06-15 | Julie McHugh | Independent Chairperson | Other Acquisition | +63,481 | -- |
| 2026-06-15 | Julie McHugh | Independent Chairperson | Automatic Disposition | -21,571 | $3.73 |
| 2026-06-15 | Marla Kessler | Independent Director | Other Acquisition | +63,481 | -- |
| 2026-06-15 | Jon Duane | Independent Director | Other Acquisition | +63,481 | -- |
| 2026-05-18 | Ronald Silver | Senior VP, Interim CFO, Corporate Controller & Chief Accounting Officer | Other Acquisition | +25,000 | -- |
| 2026-03-16 | Sarissa Capital Management LP | -- | Open Market Disposition | -6,730,800 | $3.05–3.31 |
| 2026-03-12 | Alexander Denner | Independent Director | Other Acquisition | +4,451 | -- |
| 2026-03-09 | Thomas McCourt | Chief Executive Officer | Other Acquisition | +409,836 | -- |
| 2026-03-09 | Michael Shetzline | Former Chief Medical Officer, Senior VP and Head of Research & Drug Development | Other Acquisition | +136,612 | -- |
| 2026-03-09 | Ronald Silver | Senior VP, Interim CFO, Corporate Controller & Chief Accounting Officer | Other Acquisition | +163,934 | -- |
| 2026-03-09 | John Minardo | Chief Legal Officer | Other Acquisition | +136,612 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:01:04 · For reference only, not investment advice and not tailored to your situation.
Ironwood Pharmaceuticals discussion 0 comments